Services
Company
Legal and Governance
Insights / Webinars
ISPOR webinar – AI in Evidence Synthesis: Are the Robots Taking Over?
Written on Wednesday, June 18, 2025
Webinar: AI in Evidence Synthesis: Are the Robots Taking Over?
Time: 10:00AM EDT
Date: Thursday, July 10, 2025
Systematic literature reviews (SLRs) and other forms of evidence synthesis are critical components of healthcare decision-making. With the rapid expansion of available data from clinical trials to real-world evidence, the volume and complexity of evidence requiring synthesis have grown substantially in recent years. Innovations in artificial intelligence (AI) have the potential to transform evidence synthesis. Currently, total automation of evidence synthesis to exclude human intervention is infeasible; however, the areas where AI can replace or augment humans, such as SLRs and meta-analyses, are developing rapidly, although the extent is unclear.
This webinar will cover the potential of AI to augment and semi-automate evidence synthesis projects, focusing on SLRs. We will discuss the science and sentiments around implementing these capabilities, including how they are perceived by key stakeholders, such as health technology assessment (HTA) agencies. Among other topics, we will contrast the use of these technologies in the United States versus other countries, such as the United Kingdom and Germany, and discuss disease areas and fields of evidence where implementing these capabilities is a higher priority.
Learning objectives:
- Explore how AI can support SLRs, identifying which tasks are most amenable to augmentation.
- Address potential pitfalls in using AI for SLRs, including differing abilities of stakeholders to evaluate the implications of AI approaches and platforms.
- Understand differences in AI adoption for evidence synthesis and the factors influencing regional implementation.
- Explore the acceptability of AI.
- Identify priority disease areas and evidence types where AI-enabled evidence synthesis offers the most immediate value and feasibility.
Moderator/Speaker:
Grace Fox, PhD, Director, Strategic Market Access, OPEN Health
Speakers:
Nick Halfpenny, MSci, Senior Director & Joint EU Lead, Strategic Market Access, OPEN Health
Bengt Liljas, PhD, Group Director Health Economics & Payer Evidence, OMAP, AstraZeneca
At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact. By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.
OPEN Health. The right combination to unlock possibilities.
For information about OPEN Health’s services and how we could support you, please get in touch.